nav-left cat-right
cat-right

Illumina Acquires NextBio

October 28, 2013 | Illumina today announced it has signed a definitive agreement to acquire Santa Clara-based NextBio. NextBio’s powerful big-data platforms aggregate and analyze large quantities of phenotypic and genomic data for research and clinical applications. (see, “The NextBio Thing in Bioinformatics). With the addition of NextBio’s platform upon completion of the acquisition, Illumina says it will be...

Structure of active coagulation factor XIII publis...

October 14th, Darmstadt, Germany Zedira, in cooperation with the group of Prof. Gerhard Klebe in Marburg, reported the first crystal structure of coagulation factor XIII in the active conformation. The article is now published in Angewandte Chemie International Edition and provides a proprietary high-resolution structure of FXIIIa in complex with the inhibitor ZED1301 serving as lead structure. The data are of enormous value...

Battered Helicos Files for Chapter 11

Battered by years of rough financial sledding and tough competition from rival next-generation sequencing companies, Helicos Biosciences filed Thursday for protection from creditors under Chapter 11 of the U.S. Bankruptcy Code. In its filing (Case 12-19091) in U.S. Bankruptcy Court for the District of Massachusetts, Helicos listed $15.478 million in liabilities and only $3.503 million in assets. On the day of its...

StemCyte and UC Davis Tethered in Umbilical Cord B...

StemCyte entered an agreement with the UC Davis Umbilical Cord Blood Collection (UCB) Program to advance the collection, processing, and registration of high quality and diverse cord blood cells from California mothers for public banking. According to the company, the agreement is the first of its kind under California’s statewide program. Legislation signed into law in 2010 called for the University of California to...

Developing Chicken-Derived mAbs

Crystal Bioscience and Integral Molecular launched a research collaboration to generate panels of chicken monoclonal antibodies against undisclosed therapeutic GPCR and ion channel targets. According to the firms, the collaboration will leverage the synergy between Integral Molecular’s Lipoparticle technology for immunization with native conformation multispanning membrane proteins and Crystal’s GEM technology...

Developing a New Blood Test for Multiple Sclerosis

DioGenix formed an alliance with Fast Forward, a subsidiary of the National Multiple Sclerosis Society, to develop a novel blood test for multiple sclerosis (MS). Fast Forward will provide up to $500,000 as part of a Sponsored Research Agreement that will enable DioGenix to expand an ongoing clinical trial of its MS diagnostic, MSPrecise™, a next-generation sequencing assay that measures changes to the adaptive immune...
Page 10 of 147« First...89101112...203040...Last »